Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hamycin is a **polyene antifungal antibiotic** derived from *Streptomyces pimprina* and historically developed and manufactured in India, notably by Hindustan Antibiotics. It is a heptaene macrolide polyene that exists as closely related components, hamycin A and hamycin B. Its antifungal activity is mediated by binding fungal membrane sterols, particularly **ergosterol**, leading to disruption of membrane permeability and cell death. Hamycin has been used as a topical, oral, vaginal, and less commonly systemic antifungal agent for infections such as candidiasis, otomycosis, aspergillosis, and cutaneous mycoses; older reports also describe antiprotozoal activity against *Trichomonas vaginalis* and *Leishmania donovani*. Conventional parenteral use has been limited by toxicity, and liposomal formulations have been investigated to improve tolerability while preserving antifungal efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hamycin.